MARK A. GOLDSMITH - 01 Mar 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Mar 2023, 15:15:38 UTC
Previous filing
23 Feb 2023
Next filing
06 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Award $0 +104,000 +41% $0.000000 355,872 01 Mar 2023 Direct F1
holding RVMD Common Stock 40,424 01 Mar 2023 Trust F2
holding RVMD Common Stock 40,424 01 Mar 2023 Trust F3
holding RVMD Common Stock 327,547 01 Mar 2023 Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Award $0 +363,000 $0.000000 363,000 01 Mar 2023 Common Stock 363,000 $26.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 215,500 restricted stock units.
F2 Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F3 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F4 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F5 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

President and Chief Executive Officer